Zio Health

Biotechnology company focused on producing diagnostic and monitoring devices

Operating in hard tech based in United Kingdom, Zio Health was founded in 2016.

Profile

ZIO health’s proprietary pocket-sized technology brings lab testing to the point of care to improve patient outcomes. Using ZiO’s technology, we developed a therapeutic Drug Monitoring device – A powerful tool for dose individualisation to enhance drug efficacy. Our therapeutic drug monitoring (TDM) device quantitatively tests medication levels at the point-of-care. Using machine learning algorithms, we combine the real-time test results with the patients’ unique profile to accurately provide dosing information. We are testing various medications with a narrow therapeutic range in which medications need to be tested daily due to the high risk of overdosing that leads to toxicity. ZiO Health’s Vancomycin TDM POC Device: Some medications like Vancomycin have a small difference between the minimum effective concentration and the minimum toxic concentration in the blood. 60% of the vancomycin doses are not in therapeutic range and ~20% of the doses are administered in the toxic range, leading to adverse drug effects i.e. nephrotoxitiy. Current testing methods test for ‘total vancomycin’ levels, rather than the active form, free vancomycin, which leads to further inaccurate dosing. The

Its activity falls under hard tech; the profile below is assembled from public directory data.

Its base of operations is United Kingdom.

The company is listed at the SOSV portfolio company stage of development.

Recorded headcount: 11-50 employees.

Website: zio-health.com